Stock BSX BOSTON SCIENTIFIC CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Boston Scientific Corporation

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
73.17 USD -0.12% Intraday chart for Boston Scientific Corporation +8.67% +26.57%
Apr. 26 Daiwa Adjusts Price Target on Boston Scientific to $81 From $73 MT
Apr. 26 Redburn Atlantic Adjusts Price Target on Boston Scientific to $79 From $75 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,029 51,478 60,534 66,273 84,691 107,552 - -
Enterprise Value (EV) 1 72,820 58,887 67,674 74,280 92,928 113,563 110,900 107,525
P/E ratio 13.6 x -300 x 61.6 x 103 x 54 x 50.8 x 41.1 x 34.3 x
Yield - - - - - - - -
Capitalization / Revenue 5.87 x 5.19 x 5.09 x 5.23 x 5.95 x 6.73 x 6.15 x 5.62 x
EV / Revenue 6.78 x 5.94 x 5.69 x 5.86 x 6.53 x 7.11 x 6.34 x 5.62 x
EV / EBITDA 23.4 x 19.4 x 16.5 x 20.8 x 22.6 x 24.6 x 21.3 x 18.4 x
EV / FCF 53 x 52 x 51.4 x 79.2 x 51.9 x 50.9 x 35 x 29.5 x
FCF Yield 1.89% 1.92% 1.94% 1.26% 1.93% 1.97% 2.86% 3.39%
Price to Book 4.54 x 3.32 x 3.64 x 3.77 x 4.39 x 5.04 x 4.47 x 3.87 x
Nbr of stocks (in thousands) 1,393,824 1,431,921 1,424,992 1,432,311 1,464,983 1,469,895 - -
Reference price 2 45.22 35.95 42.48 46.27 57.81 73.17 73.17 73.17
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10,735 9,913 11,888 12,682 14,240 15,979 17,486 19,146
EBITDA 1 3,111 3,040 4,103 3,574 4,106 4,618 5,207 5,853
EBIT 1 2,800 1,917 3,010 3,241 3,738 4,272 4,779 5,357
Operating Margin 26.08% 19.34% 25.32% 25.56% 26.25% 26.74% 27.33% 27.98%
Earnings before Tax (EBT) 1 687 -138 1,076 1,141 1,985 2,589 3,182 3,735
Net income 1 4,700 -173 985 642 1,570 2,145 2,681 3,204
Net margin 43.78% -1.75% 8.29% 5.06% 11.03% 13.43% 15.33% 16.74%
EPS 2 3.330 -0.1200 0.6900 0.4500 1.070 1.440 1.779 2.136
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,232 3,171 3,649
FCF margin 12.81% 11.42% 11.07% 7.4% 12.58% 13.97% 18.13% 19.06%
FCF Conversion (EBITDA) 44.2% 37.24% 32.07% 26.25% 43.64% 48.34% 60.89% 62.33%
FCF Conversion (Net income) 29.26% - 133.6% 146.11% 114.14% 104.06% 118.28% 113.86%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 2,932 3,127 3,026 3,244 3,170 3,242 3,389 3,599 3,527 3,725 3,856 4,018 3,955 4,169 4,209
EBITDA 1 838 1,109 1,055 898 892 928 947 1,052 1,011 1,095 1,037 1,142 1,133 1,221 1,321
EBIT 1 750 819 781 818 810 833 865 964 919 990 1,012 1,071 1,053 1,140 1,123
Operating Margin 25.58% 26.19% 25.81% 25.22% 25.55% 25.69% 25.52% 26.79% 26.06% 26.58% 26.24% 26.64% 26.64% 27.34% 26.68%
Earnings before Tax (EBT) 1 483 120 156 345 245 396 444 426 610 505 608 769 744 830.7 684.5
Net income 1 405 80 97 246 174 126 300 261 505 504 495 530.3 516.4 586 611
Net margin 13.81% 2.56% 3.21% 7.58% 5.49% 3.89% 8.85% 7.25% 14.32% 13.53% 12.84% 13.2% 13.06% 14.06% 14.52%
EPS 2 0.2800 0.0600 0.0700 0.1700 0.1200 0.0900 0.2100 0.1800 0.3400 0.3400 0.3300 0.3540 0.3453 0.3963 0.4042
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/27/21 2/2/22 4/27/22 7/27/22 10/26/22 2/1/23 4/26/23 7/27/23 10/26/23 1/31/24 4/24/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 9,791 7,409 7,140 8,007 8,237 6,011 3,348 -
Net Cash position 1 - - - - - - - 27.3
Leverage (Debt/EBITDA) 3.147 x 2.437 x 1.74 x 2.24 x 2.006 x 1.302 x 0.6429 x -
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,232 3,171 3,649
ROE (net income / shareholders' equity) 19.8% 9.44% 14.1% 14.4% 16.3% 16.3% 16.8% 16.4%
ROA (Net income/ Total Assets) 8.67% 4.49% 7.42% 7.6% 8.87% 8.42% 9.37% 8.2%
Assets 1 54,241 -3,851 13,284 8,446 17,696 25,482 28,610 39,078
Book Value Per Share 2 9.950 10.80 11.70 12.30 13.20 14.50 16.40 18.90
Cash Flow per Share 2 1.300 1.060 1.300 1.060 1.710 2.560 2.940 3.350
Capex 1 461 376 554 588 711 672 706 734
Capex / Sales 4.29% 3.79% 4.66% 4.64% 4.99% 4.2% 4.04% 3.84%
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Boston Scientific Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
73.17 USD
Average target price
80.08 USD
Spread / Average Target
+9.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
ILLUMINA, INC. Stock Illumina, Inc.
-12.18% 19.47B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. BSX Stock
  4. Financials Boston Scientific Corporation